Tirzepatide for Sleep Apnea
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Tirzepatide in Sleep Apnea grades Tier A — moderate evidence. Effective, but with safety or population caveats.
A 🔵 A Moderate Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.72
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
90%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.722
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
Finding: Pooling 5 RCTs (n=1024), incretin-based therapies (incl. tirzepatide) reduced AHI by a mean difference of -11.61 events/h vs placebo (95% CI -22.91 to -0.31, p=0.046), confirming a clinically meaningful but heterogeneous reduction in OSA severity.
View on PubMed Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis
Finding: Across 6 trials (n=1067), incretin therapies reduced AHI by -9.48 events/h vs placebo (95% CI -12.56 to -6.40), with tirzepatide showing the largest subgroup effect (-21.86 events/h) versus liraglutide (-5.10 events/h).
View on PubMed Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
Finding: In two phase-3 double-blind placebo-controlled trials (n=469; Trial 1 no-PAP, Trial 2 on-PAP), tirzepatide cut AHI by an estimated 20.0 events/h beyond placebo in Trial 1 (95% CI -25.8 to -14.2) and 23.8 events/h in Trial 2 (95% CI -29.6 to -17.9), both P<0.001.
View on PubMed Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
Finding: In this prespecified secondary analysis of SURMOUNT-OSA (n=469), tirzepatide produced greater improvement in cardiometabolic risk factors than placebo, with combined weight-plus-OSA change significantly mediating the systolic blood pressure reduction (no significant mediation for diastolic BP).
View on PubMed Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight
Finding: This SURMOUNT-OSA secondary analysis (n=469) showed AHI improved progressively over 52 weeks and tracked the magnitude of body-weight loss, indicating the OSA benefit is largely weight-mediated rather than independent of weight change.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell … source↗
L4b EU EFSA
Supportive
Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct… source↗
L4c UK NHS
Supportive
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity. If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue tre… source↗
L4d TW TFDA / 衛福部
Supportive
猛健樂注射劑15毫克/0.5毫升 (MOUNJARO Injection 15mg/0.5mL)；許可證字號：衛部藥輸字第028468號；限由醫師使用；適應症：(1) 作為飲食及運動療法之外的輔助治療，用於改善第二型糖尿病成人病人之血糖控制；(2) 作為飲食及運動療法之外的輔助治療，用於體重控制（肥胖或過重）；申請商：台灣禮來股份有限公司；發證日期：112-07-19 source↗
L4e WHO
Supportive
Tirzepatide (GLP-1/GIP dual receptor agonist) used as glucose lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity. High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines. source↗
L5a NIH Office of Dietary Supplements
Supportive
Tirzepatide functions as a dual agonist with greater affinity to GIP receptors than to GLP-1 receptors. FDA approvals: Type 2 Diabetes (Mounjaro) - May 2022 as adjunct to diet and exercise for glycemic control; Obesity (Zepbound) - November 2023 for chronic weight management in adults with obesity or overweight plus comorbidities; Obstructive Sleep Apnea (Zepbound) - December 2024 for moderate-… source↗
L5b Mayo Clinic
Supportive
Tirzepatide injection is used to treat type 2 diabetes and is used together with diet and exercise to help control blood sugar. Additionally, tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions. It is also used to treat moderate to severe obstructive sleep apnea (OSA) in patients with obesity. source↗
L5c Cleveland Clinic
Supportive
It can be used to treat sleep apnea. source↗
L5d Harvard Health
Supportive
Those treated with tirzepatide had a nearly 59% drop in their apnea-hypopnea index, which measures the number of times a person's breathing slows or stops during an hour of sleep. Additionally, those taking tirzepatide lost close to 20% of their body weight. Several patients lost between 50 and 60 pounds, which was enough to completely cure their sleep apnea. While tirzepatide is not approved f… source↗
L5e Specialty Society (condition-mapped)
Supportive
The FDA approval of Zepbound for moderate to severe obstructive sleep apnea in adults with obesity is a positive development for patients and clinicians. [Zepbound is] only effective for cases of sleep apnea that are related to obesity. While Zepbound can reduce the severity of sleep apnea, it may not cure the disease. The goal of tirzepatide therapy is not to replace traditional OSA treatments… source↗